Are academic hospitals better at treating metastatic colorectal cancer?

被引:9
|
作者
Atallah, Chady [1 ]
Oduyale, Oluseye [1 ]
Stem, Miloslawa [1 ]
Eltahir, Ahmed [1 ]
Almaazmi, Hamda H. [1 ,2 ]
Efron, Jonathan E. [1 ]
Safar, Bashar [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Surg, Colorectal Res Unit,Ravitch Colorectal Div, Baltimore, MD 21205 USA
[2] George Washington Univ, Sch Med & Hlth Sci, Dept Surg, Washington, DC 20052 USA
关键词
FACILITY TYPE; MULTIDISCIPLINARY MANAGEMENT; CASE VOLUME; OUTCOMES; SURVIVAL; STAGE; SURGEON; IMPACT; DIAGNOSIS; RESECTION;
D O I
10.1016/j.surg.2020.05.023
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: There is a strong association between hospital volume and surgical outcomes in resectable colorectal cancer. The purpose of our study was to investigate the association between hospital facility type and survival of patients with metastatic colorectal cancer. Methods: Adults from the National Cancer Database (2010-2015) with a primary diagnosis of colorectal metastases were included and stratified by facility type: community cancer program, comprehensive community cancer program, and academic/research program. The primary outcome was 5-year overall survival, analyzed using Kaplan-Meier survival curves, log-rank test, and the Cox proportional hazards regression model. Results: Among the 52,958 included patients, 13.72% were treated at a community cancer program, 49.89% at a comprehensive community cancer program, and 36.29% at an academic/research program. A significant increase in the proportion of patients being treated in an academic/research program has been observed from 2010 to 2015. An academic/research program tended to use more chemotherapy with colorectal radical resection and liver or lung resection and immunotherapy with chemotherapy. In adjusted analysis, the academic/research program had decreased risk of mortality in comparison to the community cancer program and the comprehensive community cancer program (hazard ratio 0.90, 95% confidence interval 0.86-0.94; 0.87, 0.85-0.90; each P < .001; respectively). Similar results were seen after stratifying by metastatic site and treatment type. Conclusion: The prognosis and overall survival of patients with metastatic disease is better in an academic/research program compared with a community cancer program or a comprehensive community cancer program, with this difference persisting across sites of metastatic disease and treatment types. Further studies are required to validate these results and investigate disparities in the management of metastatic colorectal cancer. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:248 / 256
页数:9
相关论文
共 50 条
  • [1] Immunotherapy for treating metastatic colorectal cancer
    Boghossian, Shahe
    Robinson, Stuart
    Von Delwig, Alexei
    Manas, Derek
    White, Steve
    [J]. SURGICAL ONCOLOGY-OXFORD, 2012, 21 (02): : 67 - 77
  • [2] Cost of treating metastatic colorectal cancer: a systematic review
    Bhimani, N.
    Wong, G. Y. M.
    Molloy, C.
    Pavlakis, N.
    Diakos, C. I.
    Clarke, S. J.
    Dieng, M.
    Hugh, T. J.
    [J]. PUBLIC HEALTH, 2022, 211 : 97 - 104
  • [3] Molecular Approaches to Metastatic Colorectal Cancer: Better Diagnosis - Better Treatment?
    Seufferlein, Thomas
    Simoes, Carolina
    Kude, Fernando
    Ettrich, Thomas J.
    [J]. VISCERAL MEDICINE, 2019, 35 (04) : 259 - 264
  • [4] Research on the Efficacy of Anlotinib in Treating Advanced Metastatic Colorectal Cancer
    Zhang, Faliang
    Qiao, Jinpeng
    [J]. INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 85 : 242 - 247
  • [5] Unraveling the Complexities of Treating Metastatic Colorectal Cancer With Angiogenesis Inhibitors
    Overstreet, Karen
    Van Cutsem, Eric
    Johnson, Monique
    [J]. CLINICAL COLORECTAL CANCER, 2015, 14 (03) : 131 - 132
  • [6] Role of capecitabine in treating metastatic colorectal cancer in Chinese patients
    Wang, Feng
    Wang, Feng-Hua
    Bai, Long
    Xu, Rui-Hua
    [J]. ONCOTARGETS AND THERAPY, 2014, 7 : 501 - 511
  • [7] Metastatic colorectal cancer: therapeutic options for treating refractory disease
    Parmar, A.
    Chan, K. K. W.
    Ko, Y. J.
    [J]. CURRENT ONCOLOGY, 2019, 26 : S24 - S32
  • [8] Integrating Systemic and Surgical Approaches to Treating Metastatic Colorectal Cancer
    Mi, Kaihong
    Kalady, Matthew F.
    Quintini, Cristiano
    Khorana, Alok A.
    [J]. SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2015, 24 (01) : 199 - +
  • [9] Panitumumab: leading to better overall survival in metastatic colorectal cancer?
    Sebio, Ana
    Stintzing, Sebastian
    Stremitzer, Stefan
    Zhang, Wu
    Lenz, Heinz-Josef
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (04) : 535 - 548
  • [10] Treatment and outcomes of metastatic colorectal cancer patients in public and private hospitals: results from the South Australian Metastatic Colorectal Cancer Registry
    McNeill, David
    Karapetis, Christos S.
    Price, Timothy J.
    Meagher, Philip
    Piantadosi, Cynthia
    Quinn, Stephen
    Roder, David
    Padbury, Rob
    Maddern, Guy
    Townsend, Amanda
    Jayawardana, Madawa W.
    Roy, Amitesh C.
    [J]. INTERNAL MEDICINE JOURNAL, 2021, 51 (01) : 69 - 77